Announcements Trials

Browse Landscape

Phase

Phase 3 3 Phase 2 3 Phase EARLY_PHASE1 1 Phase 4 1 Phase 1/2 1 Phase 1 1

Status

Unknown 1 Recruiting 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Cyclophosphamide 37 Gemcitabine 31 Paclitaxel 28 Cisplatin 28 Carboplatin 27 Capecitabine 27 camrelizumab 25 Nivolumab 24 apatinib 23 Oxaliplatin 21 fludarabine 20 Radiotherapy 20 toripalimab 19 Drug Therapy 18 Immunotherapy, Adoptive 17 pembrolizumab 16 Docetaxel 16 Bevacizumab 16 Dexamethasone 15 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 14 Injections 14 tislelizumab 13 Temozolomide 13 Rituximab 13 Cetuximab 13 Irinotecan 12 Fluorouracil 11 130-nm albumin-bound paclitaxel 11 anlotinib 10 Trastuzumab 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Unknown × Denosumab × Clear all

NCT03161756 2022-04-07

CHARLI

Melanoma and Skin Cancer Trials Limited

Phase 1/2 Unknown

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡